We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor.
- Authors
Joensuu, Heikki; Eriksson, Mikael; Sundby Hall, Kirsten; Hartmann, Jörg T.; Pink, Daniel; Schütte, Jochen; Ramadori, Giuliano; Hohenberger, Peter; Duyster, Justus; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Sarlomo-Rikala, Maarit; Nilsson, Bengt; Sihto, Harri; Monge, Odd R.; Bono, Petri; Kallio, Raija; Vehtari, Aki
- Abstract
The article discusses a study that compared the effects of one year and three years of adjuvant treatment with the drug imatinib for patients with operable gastrointestinal stromal tumor (GIST). The study was performed in 24 hospitals in Finland, Germany, Norway and Sweden and involved patients who underwent surgical removal of KIT-positive GIST and were at risk of GIST recurrence. It was found that 333 of 366 tumors available for testing had KIT or platelet-derived growth factor receptor-α (PDGFRA) mutation. Patients assigned for three years of imatinib treatment showed longer recurrence-free survival (RFS) than those assigned for one year of treatment.
- Subjects
SWEDEN; FINLAND; GERMANY; NORWAY; GASTROINTESTINAL stromal tumors; TUMOR treatment; ADJUVANT treatment of cancer; IMATINIB
- Publication
JAMA: Journal of the American Medical Association, 2012, Vol 307, Issue 12, p1265
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2012.347